Quetiapine for the treatment of cocaine dependence: An open-label trial

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 221-224

  Kennedy, Annette ^a,b,c,e   Wood, Amanda Ernst ^a,b,d   Saxon, Andrew J ^a,d   Malte, Carol ^a   Harvey, Megan ^a,b   Jurik, Jennifer ^a,b   Kilzieh, Nael ^a,b,d   Lofgreen, Cassin ^a,b   Tapp, Andre ^a,b,d  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b Veterans Affairs Puget Sound Health Care System   (United States)

^c Seattle Institute for Biomedical and Clinical Research   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Puget Sound Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; QUETIAPINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FAINTNESS; HUMAN; MALE; MOTOR DYSFUNCTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; COCAINE-RELATED DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SEVERITY OF ILLNESS INDEX; SYNCOPE; TABLETS; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

EID: 40949128787     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318166f50d     Document Type: Article

References (23)

1. Farren CK, Hameedi FA, Rosen MA, et al. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend. 2000;59:153-163.
2. Roy A, Roy M, Smelson DA. Risperidone, ERG and cocaine craving. Am J Addict. 1998;7:90.
3. Smelson DA, Roy A, Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry. 1997;42:984.
4. Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27:45-49.
5. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol. 2000;20:305-310.
6. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265-273.
7. Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction. 2005;100(1 suppl):43-57.
8. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161-166.
9. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
10. Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:532-535.
11. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci. 2004;29:452-457.
12. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002;4:406-411.
13. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc; 1997.
14. Somoza E, Baker S, Himmler C, et al. The Brief Substance Craving Scale - measuring craving in clinical trials. NIDA Res Monogr. 1999;180:304.
15. Sobell LC, Sobell MB. Timeline Followback User's Guide: A Calendar Method for Assessing Alcohol and Drug Use. Toronto: Addictions Research Foundation; 1996.
16. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
17. Overall JE, Gorman DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
18. CGI: Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharamacology, rev. ed. (DHEW Publ No ADM 76-338). Rockville, MD: US Dept. of Health, Education, and Welfare; 1976:218-222.
19. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247-265.
20. The Abnormal Involuntary Movement Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharamacology, rev. ed. (DHEW Publ No ADM 76-338). Rockville, MD: US Dept. of Health, Education, and Welfare; 1976:534-537.
21. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(7 suppl):22-31.
22. Casey DE, Haupt DW, Newcomer JW, et al Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(7 suppl):4-18.
23. Nunes EV. Methodologic recommendations for cocaine abuse clinical trials: a clinician-researcher's perspective. NIDA Res Monogr. 1997;175:73-79.